Boston Scientific Corporation research snapshot
BSX AI stock analysis currently reads Boston Scientific Corporation as a high-quality medical technology compounder whose operating business is stronger than its damaged chart. The company reported Q1 2026 net sales of $5.203 billion, up 11.6% year over year, with cardiovascular growth leading the mix. The stock analysis is scenario-based rather than a fixed price prediction: the upside case needs durable electrophysiology, Watchman, endoscopy, and urology growth, while the downside case is tied to guidance cuts, procedure-volume risk, regulatory surprises, and a technical failure below recent lows.
Current price
$45.30
Market cap
$67.33 billion calculated, $67.72 billion reported reference
AI score
74 / 100
Rating
Quality medtech franchise, valuation reset watch
Trend status
Mixed technical trend: price is near short-term support, above one 50-day feed, but below the 200-day moving average in the Investing.com snapshot
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Boston Scientific sells mission-critical medical devices across cardiovascular, endoscopy, urology, neuromodulation, and related procedure categories, with recurring procedure demand rather than one-time consumer demand. | High |
| Moat | The moat comes from clinical evidence, physician familiarity, regulatory approvals, manufacturing quality, global sales scale, product breadth, and acquired technology platforms such as electrophysiology and stroke prevention. | High |
| Management | Management has a long record of portfolio expansion and innovation, but the 2026 guidance reset raises the bar for capital allocation, integration, and forecast credibility. | Medium-high |
| Financial trend | Q1 2026 net sales rose 11.6% to $5.203 billion, with MedSurg up 7.8% and Cardiovascular up 13.5%, while full-year 2026 sales guidance was reset to 7.0% to 8.5% reported growth. | High |
| Valuation | At $45.30 and an adjusted 2026 EPS guide midpoint near $3.375, BSX trades near 13.4x forward adjusted EPS, while TTM valuation estimates near 19x earnings and 3.3x sales depend on data source and GAAP adjustments. | Medium |
| Technical trend | The chart is not clean. BSX has bounced from recent lows, but July 2026 technical feeds still show resistance around the 200-day moving average and conflicting 50-day signals. | Medium |
| Risk level | Main risks are procedure slowdowns, product recalls, FDA or international regulatory setbacks, reimbursement pressure, acquisition integration, litigation, debt after acquisitions, and another estimate reset. | Medium-high |
| AI confidence | Data confidence is high for reported facts and medium for forward price paths because guidance, analyst targets, and technical feeds moved sharply after the 2026 reset. | High data confidence |
| Investment certainty | BSX is a strong medtech business, but a buy decision still needs evidence that the guidance reset is conservative and that the stock can reclaim medium-term trend support. | Medium |
BSX AI stock forecast
The BSX AI stock forecast uses scenario math around the $45.30 price reference, the company adjusted 2026 EPS guidance midpoint near $3.375, and a three-year earnings multiple framework. The audited model produced a bearish area near $38, a base area near $74, and a bullish area near $108 before any future capital allocation effects.
$95 to $110
More likely if 2026 guidance proves conservative, electrophysiology and Watchman growth remain strong, MedSurg keeps mid-single-digit growth, margins expand, debt leverage falls, and investors restore a low-to-mid 20s earnings multiple.
$68 to $78
More likely if sales grow near management guidance, adjusted EPS compounds in high single digits, acquisitions are integrated without new write-downs, and the market values BSX near a high-teens forward earnings multiple.
$35 to $42
More likely if the guidance reset is followed by another cut, cardiovascular growth slows, device safety or regulatory issues appear, debt pressure limits flexibility, or BSX is re-rated toward a low-teens earnings multiple.
BSX AI technical analysis
BSX AI technical analysis is mixed as of the July 8, 2026 cutoff. MarketWatch showed a July 7 close near $45.30 after a 1.57% gain, while Investing.com listed a 14-day RSI near 58.5, a 50-day moving average near $44.11, and a 200-day moving average near $46.95. This creates a short-term rebound but not a confirmed long-term uptrend.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $45.30 | MarketWatch July 7, 2026 close used as the current price reference for this page. |
| Immediate support | $44.50 to $44.60 | Anchored to the July 6 close near $44.60 and the lower part of the July 7 trading area. |
| Secondary support | $42.25 to $43.00 | MarketWatch cited a recent 52-week low near $42.25. A break below this zone would weaken the recovery setup. |
| Near resistance | $46.30 to $47.00 | The July 7 intraday high was near $46.32, and Investing.com listed the 200-day moving average near $46.95. |
| Moving averages | 50-day near $44.11, 200-day near $46.95 | Investing.com showed price above the 50-day moving average but below the 200-day moving average. Other technical feeds showed different 50-day values, so this is a medium-confidence input. |
| Momentum | RSI near 58.5 | The Investing.com 14-day RSI snapshot suggests short-term momentum improved from oversold conditions without reaching a classic overbought reading. |
| Volume and volatility | 12.8 million shares versus 21.6 million 50-day average | MarketWatch reported July 7 volume below the 50-day average, so the rebound still needs stronger participation to confirm. |
| Invalidation | Close below $42.25 | A close below the cited 52-week low would invalidate the current rebound framework and shift attention to capital preservation. |
BSX AI trading strategy
The BSX AI trading strategy below is a rules-based research framework, not personal advice. It links Boston Scientific fundamentals, guidance revisions, medtech peer action, and technical confirmation with predefined invalidation levels.
Watch for BSX to reclaim and hold $47, which would put price back above the cited 200-day moving average area. Confirmation should come with stronger volume, stable 2026 EPS guidance, and no new product or regulatory setback.
A failed move back below $44.50 after testing $47 should reduce setup confidence because it would show supply still dominates the rebound.
If BSX retests $42.25 to $43.00 without another guidance cut or device-risk disclosure, compare the reaction with medtech peers, analyst revisions, procedure-volume data, and cardiovascular segment commentary.
Do not treat the pullback as benign if price closes below the cited 52-week low or if management lowers growth expectations again.
Track Q2 2026 sales growth, adjusted EPS, MedSurg growth, Cardiovascular growth, Watchman and electrophysiology momentum, gross margin, operating margin, free cash flow, debt reduction, and acquisition integration updates.
Position sizing should reflect medical-device regulatory risk, product-liability risk, reimbursement pressure, and technical volatility after the 2026 reset.
Investment research summary
Boston Scientific sells specialized medical devices that help physicians treat complex cardiovascular, digestive, urological, neurological, respiratory, and oncological conditions. Customers pay because hospitals and physicians need reliable devices with clinical evidence and procedural support.
The moat is strongest in physician training, regulatory approvals, clinical data, product breadth, supply reliability, global commercial scale, and switching friction inside procedure workflows. It is weaker where competitors can copy features or compete on price.
The thesis fails if growth platforms disappoint, recalls damage trust, reimbursement lowers procedure economics, debt or acquisitions reduce flexibility, or investors decide the company deserves a much lower medtech multiple.
Management has compounded through internal innovation and acquisitions, with Q1 2026 showing strong sales growth. The key test is whether the 2026 guidance reset was conservative rather than the start of a longer slowdown.
The long-term trend is favorable because aging populations, minimally invasive procedures, electrophysiology demand, stroke prevention, and chronic disease treatment expand medtech demand. The offset is heavy regulation and payer scrutiny.
At $45.30, BSX has a lower multiple than many high-quality medtech compounders, but the margin of safety depends on whether adjusted EPS guidance near $3.34 to $3.41 can hold and grow after the reset.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $45.30 close on July 7, 2026 | MarketWatch BSX daily market report | July 8, 2026 |
| Shares outstanding | 1,486,355,179 shares outstanding as of April 29, 2026 | Boston Scientific Q1 2026 Form 10-Q | July 8, 2026 |
| Market capitalization verification | $67.33 billion calculated from $45.30 x 1,486,355,179 shares, compared with a $67.72 billion reported reference | Pineify financial_rigor.py and Robinhood quote snapshot | July 8, 2026 |
| Q1 2026 net sales | $5.203 billion, up 11.6% reported year over year | Boston Scientific Q1 2026 earnings release | July 8, 2026 |
| Q1 2026 segment sales | MedSurg $1.701 billion and Cardiovascular $3.503 billion | Boston Scientific Q1 2026 Form 10-Q | July 8, 2026 |
| Q1 2026 GAAP net income | $1.341 billion attributable to Boston Scientific common stockholders | Boston Scientific Q1 2026 earnings release | July 8, 2026 |
| Cash and equivalents | $1.453 billion as of March 31, 2026 | Boston Scientific Q1 2026 Form 10-Q | July 8, 2026 |
| 2026 guidance | Full-year reported sales growth of about 7.0% to 8.5% and adjusted EPS of $3.34 to $3.41 | Boston Scientific Q1 2026 earnings release | July 8, 2026 |
| Technical moving averages | 14-day RSI near 58.5, 50-day moving average near $44.11, and 200-day moving average near $46.95 | Investing.com BSX technical snapshot | July 8, 2026 |
| Analyst target range | MarketBeat consensus price target $82.12, with low $55.00 and high $118.00 | MarketBeat BSX analyst forecast | July 8, 2026 |
This BSX AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if earnings, guidance, regulation, medical-device safety, reimbursement, interest rates, or market conditions change.
